We compared characteristics and outcomes of breast cancer patients ( n = 1325 ) who participated in a randomized clinical trial ( Tamoxifen Exemestane Adjuvant Multinational trial ) with unselected breast cancer patients of corresponding age from the general population ( n = 1056 ) .